(1R)-3-Cyclohexene-1-carboxylic acid:Exports & Compliance White Paper 2026

I. Executive Summary

(R)-Cyclohex-3-ene-1-carboxylic acid (CAS 5709-98-8) is one of those deceptively small chiral building blocks whose commercial value is governed almost entirely by a single number: the enantiomeric excess. With the molecular formula C7H10O2 and a molecular weight of 126.15 g/mol, the substance combines a carboxylic acid function, a stereogenic C1 ring carbon and a beta,gamma-unsaturated alkene in a compact alicyclic frame. Buyers sourcing it are rarely buying commodity tonnage; they are buying stereochemical information that must survive every subsequent step of a multi-stage synthesis.

The 2026 sourcing environment is shaped by three forces. First, the migration of custom synthesis and process development work toward Asian CDMOs has widened the supplier base while compressing prices for racemic material, leaving enantiopure grades as the margin pool. Second, regulated-market buyers now require that the chiral analytical method be validated and transferred with the product rather than merely quoted on a certificate of analysis. Third, the impurity conversation has moved beyond assay to include double-bond positional isomers, residual solvents and elemental impurities under ICH Q3C and Q3D.

This white paper treats the molecule as what it is: a chiral, alkene-functionalised carboxylic acid building block supplied either as a research-grade material for route scouting or as a GMP-relevant intermediate for registered pharmaceutical and agrochemical programmes. Manufacturing chemistry is discussed only at route-class level, and the technical core is deliberately focused on enantiomeric excess control, how that excess is measured, and the mechanisms by which it is retained or eroded through downstream chemistry.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The commercial specification is unusually tight because three structural features interact: the ring alkene is both a synthetic handle and a latent impurity source, the carboxylic acid is the coupling point, and the C1 stereocentre is the reason the molecule is bought at all. Commercial grades are typically colourless to pale yellow liquids or low-melting solids with a boiling point near 238 °C, a density of roughly 1.09 g/cm3 at 20 °C, an acid pKa in the region of 4.6, and a specific rotation whose sign and magnitude must always be quoted together with the solvent, concentration and wavelength used.

• The C3-C4 Alkene as a Functionalisation Handle: The isolated double bond supports epoxidation, syn-dihydroxylation, hydroboration-oxidation, ozonolytic cleavage to a dialdehyde or diacid fragment and cross-metathesis, and after hydrogenation gives access to saturated cyclohexane carboxylic acid scaffolds. It is the handle that turns this material into a precursor for substituted cyclohexane and piperidine-type ring systems widely used in medicinal chemistry.
• A beta,gamma-Unsaturated Acid with Real Racemisation Risk: Because the alkene sits beta,gamma to the carboxyl group, base, heat or prolonged warm storage can migrate it into conjugation to give the cyclohex-2-ene isomer. Conjugation converts C1 into an sp2 carbon and destroys the stereocentre outright, so double-bond positional isomer specification is a stereochemical control issue rather than a cosmetic one.

2.2 Synthesis and Manufacturing Technologies

Industrial supply is dominated by two strategic choices: build the ring and then create or resolve the stereocentre, or carry the stereocentre in from an enantiopure starting material. Both strategies converge on the same controlling operation, an enantiomeric purification step, and both generate the same characteristic impurity families that a buyer must specify against in the purchase agreement.

• Diels-Alder Ring Construction: The route class of choice for the racemic skeleton is a Diels-Alder cycloaddition of a butadiene-type diene with an acrylic acid or acrylate dienophile, delivering the cyclohex-3-ene carboxylate framework in a single step. Asymmetric variants using chiral Lewis-acid catalysis exist but are rarely economic at scale, so most producers take the racemate and then upgrade it.
• Resolution and Asymmetric Upgrading Options: Three upgrading route classes are used: classical diastereomeric salt resolution with an enantiopure amine base, enzymatic or lipase-mediated kinetic resolution of the ester, and asymmetric hydrogenation of an aromatic precursor. Salt resolution is robust and cheap but discards half the mass unless the unwanted enantiomer is racemised and recycled, while enzymatic routes are cleaner and increasingly preferred for GMP campaigns.

2.3 Core Application Matrix

• Chiral Pharmaceutical Intermediates: Enantiopure cyclohexene and saturated cyclohexane carboxylic acid fragments appear in discovery programmes targeting sp3-rich scaffolds and in piperidine-type building blocks made by ring nitrogen insertion. Buyers typically start at gram scale and then qualify a kilogram-scale campaign.
• Agrochemical Chiral Building Blocks: Alicyclic carboxylic acids are consumed in the development of chirally defined crop-protection candidates, where a single-enantiomer registration dossier and the reduced environmental load of an enantiopure active are genuine commercial arguments. Volumes are larger than in pharma but the ee requirement is equally strict.
• Auxiliaries, Ligands and Chiral Reference Standards: The acid is converted to amides, esters, alcohols and aldehydes used as resolving-agent precursors, ligand fragments, and as reference material for chiral method development, ee calibration and instrument qualification.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand tracks the broader shift toward saturated, three-dimensional scaffolds in drug discovery and the steady outsourcing of chiral route development to specialist CDMOs. Because the molecule is consumed early in a synthesis, order patterns are lumpy: a discovery-phase buyer takes tens of grams, a process-development buyer takes kilograms under a tech-transfer agreement, and a commercial campaign takes multi-kilogram quantities under a validated, change-controlled specification. That step-function demand profile makes capacity planning and inventory discipline more important than headline price.

3.2 Capacity Distribution and Export Flows

Racemic cyclohex-3-ene carboxylic acid capacity is concentrated in China, where integrated fine-chemical producers can source acrylate and diene feedstocks locally and run the cycloaddition at scale. Enantiopure upgrading capacity is distributed differently: classical salt resolution is widely available in China and India, whereas enzymatic resolution and preparative chiral chromatography at multi-kilogram scale remain concentrated in European and a smaller number of Japanese and North American specialist houses. The practical result is a two-tier market in which racemate behaves like a commodity and ee-guaranteed material behaves like a project.

3.3 Market Bifurcation and Pricing Dynamics

Price is best understood as a function of three variables rather than one: the ee level required, the analytical package attached to it, and the quality system standing behind it. A research grade at 98 percent assay with an unvalidated chiral method sits at the bottom of the range, while a GMP-made lot with full method validation, elemental-impurity data and dossier support can command a substantial multiple. Buyers who specify only an ee threshold without naming the method routinely find that two suppliers disagree by several percentage points.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

For an intermediate of this type there is no single global approval. The compliance burden is the sum of chemical inventory registration, hazard communication, and the pharmaceutical quality expectations the buyer's own dossier imposes. Exporters who treat REACH and TSCA as paperwork rather than as market-access gates tend to lose tenders late in the qualification cycle, after the technical work has already been done.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH Registration and Only-Representative Requirements: A non-EU manufacturer cannot register directly. Either the EU importer acts as importer-of-record under its own registration, or an only representative is appointed to hold the registration, the safety data sheet and the exposure scenarios. Buyers should ask for the registration number and tonnage band, because coverage determines what the downstream user may lawfully do.
• CLP Classification and Extended Safety Data Sheets: The substance is supplied under a harmonised or self-classification as an irritant or corrosive carboxylic acid with the corresponding skin and eye hazard statements. Registered volumes bring exposure-scenario-based extended safety data sheets, which downstream users must integrate into their own chemical safety assessment and, where relevant, into their site risk assessment.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA Inventory Status: Import into the United States requires that the substance appear on the active TSCA inventory or be covered by an applicable exemption, and an inventory-listing statement is a routine request in US tenders. Research quantities may fall under the research-and-development exemption, but commercial campaigns need clean, documented inventory status.
• ICH Q7, Q11, Q3C and Q3D for Pharma-Grade Campaigns: Although ICH guidelines are not chemical law, they define what a regulated buyer will accept. Q7 governs GMP once the material enters the API manufacturing chain, Q11 frames route selection and control-strategy justification, Q3C fixes residual-solvent limits by class, and Q3D sets permitted daily exposures for elemental impurities including catalyst-derived palladium, nickel and rhodium.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Environmental, social and governance review of chiral intermediate supply is no longer a formality. Buyers compiling Scope 3 inventories ask for solvent-recovery rates, process mass intensity and waste-treatment routes, and they increasingly prefer upgrading technologies that avoid stoichiometric chiral auxiliaries and the salt waste those auxiliaries generate.

5.1 Carbon Footprint and Circular Economy

The dominant carbon and waste hotspots are the resolution step, the solvent volumes used in salt formation and liberation, and the energy consumed by the multiple distillations or chromatographic passes needed to upgrade the ee. Catalytic asymmetric and enzymatic routes cut process mass intensity sharply by eliminating the discarded enantiomer stream, which is why they are being adopted despite higher development cost and longer method-development timelines.

5.2 Sustainable Sourcing and Traceability

Traceability expectations now extend to the chiral auxiliary or enzyme origin, the metal catalyst supply chain and the solvent recovery loop. Documented change control, a full impurity genealogy from starting material to shipped lot, and auditable batch records are the practical deliverables buyers request during qualification, and suppliers who can produce them on demand shorten qualification cycles by months.

VI. Supply Chain Resilience and Export Logistics

Physically the product is unremarkable; logistically the constraints concern stereochemical and chemical stability in transit. The alkene is oxidatively sensitive over long storage, the acid is hygroscopic enough to complicate assay-by-weight, and hot shipping containers accelerate double-bond migration and colour growth.

6.1 Packaging Standards and Moisture/Contamination Control

• Container Material, Headspace and Moisture Control: Amber glass, lined steel or high-density polyethylene containers with nitrogen headspace and a sealed closure are standard for development quantities; larger campaigns use lined drums with nitrogen blanketing. Copper, brass and unprotected steel fittings must be avoided because the acid attacks them and the resulting metal traces then surface in the Q3D screen.
• Salt Forms, Temperature and Retest Discipline: Where handling or weighing is difficult, the sodium salt or a crystalline amine salt can be supplied as a handling option, with the free acid liberated at the point of use. Ship and store cool, protect from light, and define a retest period that includes an ee re-check rather than assay alone.

6.2 Dangerous Goods Identification and Transit Protocols

Where the classification in force is corrosive, the substance ships as a Class 8 acidic organic liquid or solid with the corresponding UN number, packing group and packing instruction; where it is classified irritant only it may travel as a non-regulated good under limited-quantity provisions. Either way, exporters should supply a sealed container with temperature-indicator evidence for long sea legs, and the transport documentation should identify the material as a chiral intermediate with a stated ee so that substitution disputes at destination can be resolved quickly.

VII. Enterprise Global Expansion Strategy Guide

Three moves consistently separate successful chiral sourcing programmes from failed ones: writing the analytical method into the contract, qualifying a second source before the first one fails, and matching the quality system to the development phase instead of over-specifying early or under-specifying late.

1. Contract the Chiral Method, Not Just the Number: Name the chiral stationary phase or the derivatisation reagent, the sample preparation, the detection mode and the reporting convention in the purchase specification, and require method transfer data. Without this, an ee disagreement between your laboratory and the supplier's laboratory cannot be resolved at all.
2. Dual-Source with a Real Tech-Transfer Package: Qualify an alternative supplier during process development rather than after validation. The transferable package is the route description at route-class level, the impurity list with acceptance criteria, the validated chiral method, and the starting-material and catalyst specifications.
3. Run Phase-Appropriate Quality, RUO Now and GMP Later: Research-use-only material with a documented but unvalidated method is appropriate for route scouting and is materially cheaper. Move to a GMP campaign with Q7 controls, change control and impurity qualification before the material enters a regulated clinical or registration programme, and budget development time for that transition.

VIII. Conclusion

(R)-Cyclohex-3-ene-1-carboxylic acid is a small molecule whose commercial difficulty is concentrated in stereochemistry and in the honesty of the number attached to it. Suppliers who can demonstrate a validated chiral method, genuine positional-isomer control and a documented control strategy will keep winning programmes even as racemic capacity continues to commoditise.

For buyers, the 2026 agenda is straightforward: specify the method, specify the isomers, fix the solvent and elemental impurity limits, and qualify two sources before volume arrives. For producers, the complementary agenda is to move from stoichiometric salt resolution toward catalytic or enzymatic upgrading, publish real process mass intensity data, and build the quality documentation that converts an intermediate into a qualified supply position.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global (R)-Cyclohex-3-ene-1-carboxylic acid Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global (R)-Cyclohex-3-ene-1-carboxylic acid supply chain:

• China: Integrated Chiral Building-Block and Resolution Capacity: Producers in the Yangtze and Bohai Rim fine-chemical belts supply the bulk of racemic cyclohexene carboxylic acid and a growing share of resolved material, with classical salt resolution available at tonne scale and competitive pricing for 98 to 99 percent ee.
• India: CDMO-Led Custom Chiral Synthesis: Indian partners compete on route development, documentation quality and English-language regulatory support rather than on feedstock cost, and are frequently chosen as the second source when a buyer needs a full tech-transfer package and phase-appropriate GMP.
• Europe and North America: Enzymatic Resolution, Catalog and GMP Chiral Supply: European specialists supply enzymatic and chromatographic upgrading, chiral-pool technology and GMP campaigns with full ICH documentation, while North American catalog houses serve the discovery end with small packs, reference standards and chiral-method support.